Wilson Disease: Diagnosis, Management, and the Path to Cure

Wilson Disease: Diagnosis, Management, and the Path to Cure

Summary of Medical Lecture by Michael Schilsky

1. Main Clinical Topics Discussed

• Pathophysiology and normal copper metabolism
• Historical evolution of Wilson disease diagnosis
• Clinical presentations and natural history
• Diagnostic criteria and emerging biomarkers
• Treatment principles and future therapeutic directions

2. Key Learning Points, Guidelines, and Recommendations

Pathophysiology

• Wilson disease results from mutations in the ATP7B gene, encoding a copper-transporting ATPase expressed primarily in hepatocytes
• Loss of ATP7B function impairs biliary copper excretion and disrupts copper incorporation into ceruloplasmin
• Hepatic copper accumulation leads to oxidative injury to lipid membranes, proteins, and DNA
• Copper subsequently spills into systemic circulation, depositing in the brain, kidneys, and other organs
• Apoceruloplasmia (copper-deficient ceruloplasmin) has a shorter circulating half-life, explaining characteristically low serum ceruloplasmin in Wilson disease

Diagnostic Framework

• The Leipzig Criteria remain the standard diagnostic tool, integrating clinical, biochemical, and molecular data into a validated scoring system
• Key diagnostic markers include:

- Low serum ceruloplasmin (historically the first blood test developed for a genetic disease, circa 1950s)

- Elevated 24-hour urinary copper excretion

- Elevated hepatic copper on liver biopsy

- Kayser-Fleischer rings on slit-lamp examination

- ATP7B genotyping

• Relative exchangeable copper (REC): The ratio of exchangeable copper to total serum copper, developed by French groups, shows promise in differentiating Wilson disease from other copper disorders; requires external validation

Emerging Diagnostics

• A **2021 study in *Gastroenterology*** (Han et al., Seattle Children's) demonstrated that ATP7B-derived peptides recovered from blood spots and detected via monoclonal antibodies could distinguish Wilson disease patients from controls
• This methodology is under investigation for potential newborn screening applications
• Heterozygote differentiation using this assay requires further validation

Natural History

• Disease course is highly variable; even siblings carrying identical mutations may present very differently
• Sex differences: Females may experience a more accelerated hepatic course with higher rates of progression to acute liver failure compared to males
• Hepatic manifestations typically precede neuropsychiatric symptoms, occurring in the late first to second decade of life
• Neuropsychiatric symptoms typically emerge in the late second to third decade, coinciding with advanced hepatic fibrosis or cirrhosis

3. Specific Clinical Data and Study Results Cited

• ~5% of Wilson disease patients present with acute liver failure (ALF)
• ALF may be precipitated by concomitant drug-induced liver injury or viral hepatitis, triggering massive hepatocyte death and systemic copper release, resulting in characteristic Coombs-negative hemolytic anemia
• Wilson's original monograph describing the syndrome was published in 1911–1912
• Ceruloplasmin as a diagnostic marker was identified in the 1950s independently by Steinberg/Gitlin (MGH) and Bearn/Kunkel (Rockefeller)
• The ATP7B gene was simultaneously identified in the early 1990s by three independent laboratories: Gitlin (Columbia), Cox (Toronto/Edmonton), and Gitlin (Washington University, St. Louis)

4. Practical Takeaways for Clinicians

• Consider Wilson disease in any patient aged 5–40 years presenting with unexplained liver disease, neuropsychiatric symptoms, or Coombs-negative hemolytic anemia
• Apply the Leipzig Criteria systematically; do not rely on any single diagnostic marker in isolation, as ceruloplasmin alone has limited sensitivity and specificity
• Serum ceruloplasmin may be falsely elevated in the setting of inflammation (acute-phase reactant); interpret cautiously
• Evaluate non-ceruloplasmin-bound copper (free copper) as part of diagnostic workup; novel assays for exchangeable copper fraction may offer improved diagnostic accuracy
• Sex-based risk stratification: Young women with Wilson disease